[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. That moves the pharmaceutical giant and its German partner BioNTech one step closer…
[ad_1] Artur Widak | Nurphoto | Getty Images Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study. The biotech company hopes its shot, mRNA-1083, can win approval…
[ad_1] Nikos Pekiaridis | Lightrocket | Getty Images Covid vaccine makers’ shares rose Monday as new variants of the virus emerge in the U.S. ahead of the rollout of updated shots this fall. Shares of Novavax closed more than 13% higher. Moderna‘s stock closed more than 9% higher. Shares of BioNTech, which jointly develops Covid…
[ad_1] Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and…
[ad_1] A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Images Three years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is…
